First Round of Late-Breaking Clinical Trial Results Announced at VIVA22
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of three Late-Breaking Clinical Trials session at the VIVA22 conference, hosted at Wynn Las Vegas
LAS VEGAS, Nov. 1, 2022 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of three Late-Breaking Clinical Trials session at the VIVA22 conference, hosted at Wynn Las Vegas.
VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists. Below are highlights of this morning's 5 late-breaking clinical trial presentations.
A Patient-Level, Propensity-Adjusted Comparison of Drug-Coated Balloons Versus Bare-Metal Stents in Femoropopliteal Lesions: Three-Year Results in Prospective, Multicenter Studies
Presented by Mehdi Shishehbor, DO, MPH, PhD
Simultaneously published in Journal of the American College of Cardiology (JACC)
Endovascular treatment of femoropopliteal artery disease has shifted toward drug-coated balloons (DCBs); however, limited data are available regarding the safety and effectiveness of DCBs versus bare-metal stents (BMSs). Using advanced statistical methods for patient-level evaluation of prospectively collected, core laboratory–adjudicated data, this analysis demonstrated superior 12-month patency and 36-month freedom from clinically driven target lesion revascularization (CD-TLR) for DCBs compared to BMSs.
